Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Kronos Bio, Inc.    KRON

KRONOS BIO, INC.

(KRON)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/27/2020 11/30/2020 12/01/2020 12/02/2020 12/03/2020 Date
34.68(c) 32.07(c) 31.5(c) 29.28(c) 29.105 Last
95 497 178 850 115 665 137 412 59 536 Volume
+2.48% -7.53% -1.78% -7.05% -0.60% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -94,3 M - -
Net cash position 2020 344 M - -
P/E ratio 2020 -5,99x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -133 M - -
Net cash position 2021 212 M - -
P/E ratio 2021 -12,5x
Yield 2021 -
Capitalization 1 641 M 1 641 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 61
Free-Float 87,7%
More Financials
Company
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered,... 
Sector
Biotechnology & Medical Research
Calendar
12/02 | 02:15pmPresentation
More about the company
All news about KRONOS BIO, INC.
11/23KRONOS BIO : Announces Participation in Upcoming Investor Conferences
AQ
11/23Kronos Bio Announces Participation in Upcoming Investor Conferences
GL
11/18KRONOS BIO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
11/18KRONOS BIO, INC. : Results of Operations and Financial Condition, Financial Stat..
AQ
11/18Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial ..
GL
11/18KRONOS BIO : Reports Recent Business Progress and Third Quarter 2020 Financial R..
AQ
11/11KRONOS BIO : Announces Participation in the Jefferies Virtual London Healthcare ..
AQ
11/11Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare..
GL
10/22KRONOS BIO : Announces Publication of Preclinical Study Results for Investigatio..
AQ
10/22Kronos Bio Announces Publication of Preclinical Study Results for Investigati..
GL
10/14KRONOS BIO, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Ye..
AQ
10/14KRONOS BIO : Announces Closing of Initial Public Offering and Full Exercise of U..
AQ
10/14Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of ..
GL
10/08Kronos Bio Announces Pricing of Initial Public Offering
GL
More news
News in other languages on KRONOS BIO, INC.

- No features available -

More news
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 43,67 $
Last Close Price 29,28 $
Spread / Highest target 70,8%
Spread / Average Target 49,1%
Spread / Lowest Target 23,0%
EPS Revisions
Managers
NameTitle
Norbert W. Bischofberger President, Chief Executive Officer & Director
Arie S. Belldegrun Chairman
Barbara A. Kosacz Chief Operating Officer & General Counsel
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
KRONOS BIO, INC.0.00%1 641
MODERNA, INC.631.08%56 587
LONZA GROUP AG56.34%45 782
CELLTRION, INC.91.71%42 101
IQVIA HOLDINGS INC.10.05%32 601
SEAGEN INC.54.94%31 921